| Date | Title | |
| 05/22/13 | For Bifurcation Lesions in Coronary Arteries, Medtronic's Resolute Stent Delivers Strong Long-Term Results| Three Analyses Presented at EuroPCR Demonstrate Device's Durability in Addressing Common Clinical Challenge PARIS -- May 22, 2013 -- Addressing one of the most common clinical challenges in the treatment of complex coronary artery disease, three separate analyses on the program for EuroPCR this week show how strongly the Resolute drug-eluting stent from Medtronic, Inc. (NYSE: MDT) performs in coronary bifurcation lesions over the long term. Bifurcation lesions occur when plaque builds up arou... |
|  |
| 05/21/13 | Medtronic Announces CE Mark and Launch for CapSureFix Novus(TM) 5076 MRI Lead | Proven Lead Expands Access to MRI for Patients with Slow Heartbeat TOLOCHENAZ - May 21, 2013 -- Medtronic today announced CE Mark (Conformité Européenne) and launch of its CapSureFix Novus(TM)5076 Lead, which is now approved in the EU for use in an MRI environment when paired with a Medtronic MR-Conditional pacemaker. The lead has not been approved for that use in the U.S. The CapSureFix Novus 5076 Lead, previously approved for use with Medtronic's non MR-Conditional pacemakers, has long been ... |
| |
| 05/21/13 | Fourth Quarter Caps Solid Year for Medtronic| Q4 Revenue of $4.5 Billion Grew 5% at Constant Currency; 4% as Reported Q4 Non-GAAP Diluted EPS Growth of 11%; GAAP Diluted EPS Growth of 1% Q4 International Revenue Grew 7% at Constant Currency; 4% as Reported FY13 Revenue of $16.6 Billion Grew 5% at Constant Currency; 3% as Reported FY13 Free Cash Flow of $4.4 Billion; GAAP Cash Flow from Operations of $4.9 Billion Company Sets Initial FY14 Revenue Growth Outlook and EPS Guidance MINNEAPOLIS - May 21, 2013 - Medtronic, Inc. (NYSE:... |
| |
| 05/21/13 | Medtronic's Multi-Electrode, Simultaneously Firing Renal Denervation Catheter Shows Reduced Procedure Times While Demonstrating Significant Blood Pressure Reduction| Initial Results from Feasibility Study of the Symplicity Spyral(TM) Catheter Show Safety and Efficacy While More than Halving Mean Procedure Time MINNEAPOLIS and PARIS - MAY 21, 2013 - Medtronic, Inc. (NYSE: MDT) announced today preliminary results from the feasibility study of its Symplicity SpyralTM multi-electrode, 6 Fr renal denervation catheter, which showed safe, significant blood pressure reduction at one month in patients with treatment-resistant hypertension. Additionally, patients who... |
| |
| 05/21/13 | Medtronic Finds TAVI with CoreValve® System Cost Effective for Treating Patients with Severe Aortic Stenosis | EuroPCR Presentation of "Real World" ADVANCE Study Confirms Economic Value of Novel Self-Expanding Valve in Patients Unable to Undergo Surgery PARIS -- May 21, 2013 -- Focused on offering devices that provide both clinical and economic value, Medtronic, Inc. (NYSE: MDT) today unveiled the results of a cost-effectiveness model comparing transcatheter aortic valve implantation (TAVI) with the CoreValve System to medical management. Presented at EuroPCR 2013, the United Kingdom-based ana... |
| |
| 05/21/13 | Medtronic Announces Data From Largest Real-World Patient Population Confirm Strong Safety Profile and Clinical Efficacy of Renal Denervation with the Symplicity(TM) System| First Look at Data from Global SYMPLICITY Registry Shows Renal Denervation with the Symplicity(TM) System Meets Performance Expectations in Real-World Setting MINNEAPOLIS and PARIS - MAY 21, 2013 - Medtronic, Inc. (NYSE: MDT), announced today the first results from the Global SYMPLICITY Registry, which reaffirmed the safety of the renal denervation procedure with the Symplicity(TM) renal denervation system in a real-world patient population. Among the 617 registry patients with follow-up infor... |
| |
| 05/21/13 | Medtronic CoreValve ADVANCE Study Demonstrates Low Rates of Mortality and Stroke and Sustained Valve Performance| EuroPCR Presentation of One-Year Data from Robust "Real World" Global Study Demonstrates One of the Lowest Mortality Rates among Similar TAVI Studies PARIS -- May 21, 2013 -- Committed to generating robust clinical data on its CoreValve System for transcatheter aortic valve implantation (TAVI), Medtronic, Inc. (NYSE: MDT) today unveiled for the first time the complete one-year data from the "real world" Medtronic CoreValve ADVANCE Study. Presented at EuroPCR 2013, the one-ye... |
| |
| 05/20/13 | Medtronic to Honor Those Who Give Back After Receiving Life-Enhancing Medical Technology| (View the Bakken Invitation video here) Live On. Give On: Ten inspirational people will be awarded a $20,000 charitable donation and be honored at an awards celebration in Hawaii as part of the first annual Bakken Invitation MINNEAPOLIS - May 20, 2013- Medtronic, Inc. (NYSE: MDT) announced today that applications are being accepted for the inaugural Bakken Invitation, a global program designed to celebrate those who, with the help of medical technology, have overcome health challenges and ar... |
| |
| 05/20/13 | Medtronic Receives 'CE' Mark for 'Export Advance' Aspiration Catheter| Backed by Robust Clinical Data on Broad Product Family, New Thrombus Removal System Offers Superior Deliverability MINNEAPOLIS -- May 20, 2013 -- Expanding its portfolio of medical technology for the interventional treatment of cardiovascular disease, Medtronic, Inc. (NYSE: MDT) announced today that the Export Advance aspiration catheter recently received the CE (Conformité Européenne) mark and will soon be launched in Europe and other international markets. The new thrombus removal system f... |
| |
| 05/14/13 | Medtronic to Announce Financial Results for Its Fourth Quarter and Fiscal Year 2013| MINNEAPOLIS - May 14, 2013 - Medtronic, Inc. (NYSE: MDT) announced today it will report financial results for the fourth quarter and fiscal year 2013 on Tuesday, May 21, 2013. A news release will be issued at approximately 6:15 a.m. Central Time and will be available at www.medtronic.com/newsroom. The earnings news release will include summary financial information for Medtronic's fourth quarter and fiscal year, which ended April 26, 2013. Medtronic will host a webcast at 7 a.m. Central Time to... |
| |
| 05/11/13 | Biventricular Pacing Reduces Symptoms and Improves Quality-of-Life in AV Block Patients with Heart Failure and Reduced Pumping Function| New Medtronic Data Show Additional Clinical Advantages in Pacing Both Ventricles Versus Conventional Right-Ventricular Pacing MINNEAPOLIS and DENVER - May 11, 2013 - Medtronic, Inc. (NYSE: MDT) today announced new data demonstrating that simultaneously pacing the lower chambers of the heart, or biventricular (BiV) pacing with a cardiac resynchronization therapy (CRT) device, significantly improves heart failure symptoms and quality of life in a subset of heart failure patients. Findings from ... |
| |
| 05/10/13 | Data Show Medtronic-Exclusive LIA Software Detects Non-Medtronic Lead Issues at a Greater Rate Than Standard Impedance Monitoring| MINNEAPOLIS and DENVER - May 10, 2013 - Data presented today at Heart Rhythm 2013, the Heart Rhythm Society's 34th Annual Scientific Sessions, show that Medtronic, Inc. (NYSE:MDT) Lead Integrity Alert (LIA) software detected pace/sense lead issues in non-Medtronic leads at a greater rate than standard impedance monitoring alone (impedance monitoring measures the electrical continuity of a lead four times per day). The retrospective analysis, which focused on Endotak® leads (Boston Scientific) an... |
| |
| 05/10/13 | New Research Demonstrates Success of Shock Avoidance in Medtronic Defibrillators| "Shock-Less" Late Breaking Clinical Trial: Providing Clinicians with ICD Programming Reports Improves Adherence to Evidence-Based Guidelines, Reduces All-Cause Shocks PainFree SST Trial: More Than 98 Percent of Patients with SmartShock(TM) Technology Are Free of Inappropriate Shock at One Year ADVANCE III Trial: Waiting to Deliver ICD Therapy Combined with ATP During Charging(TM) Reduces the Rate of Inappropriate Shocks by 45 Percent and Reduces Rate of Hospitalization by 19 Percent ... |
| |
| 05/06/13 | Medtronic Announces FDA Approval of New Portfolio of Next-Gen Cardiac Resynchronization Therapy Devices, Implantable Cardioverter-Defibrillators|
Newly designed Devices Result in Fewer Hospitalizations for Patients, Deliver Increased Longevity, and Improved Comfort
MINNEAPOLIS - May 6, 2013 - Medtronic, Inc. (NYSE: MDT) today announced U.S. Food and Drug Administration (FDA) approval and U.S. launch of its newest cardiac devices: the Viva®portfolio of cardiac resynchronization therapy with defibrillation (CRT-D) devices, and the Evera® portfolio of implantable cardioverter-defibri... |
| |
| 05/02/13 | Medtronic Announces FDA Classification of Deep Brain Stimulation Lead Cap Communication| MINNEAPOLIS - May 2, 2013 - In keeping with its commitment to keep physicians informed about product performance and safety, Medtronic, Inc. (NYSE: MDT) issued an Urgent Medical Device Correction notification in February 2013 to provide physicians with information concerning the potential for deep brain stimulation (DBS) lead damage associated with the use of the lead cap provided in Medtronic DBS lead kits and dystonia therapy kits. The U.S. Food and Drug Administration (FDA) has classified the... |
| |
| 05/01/13 | Ten Local High School Graduates Named 2013 Medtronic Scholars| Medtronic has committed more than $1.6 million in local scholarships to 100 students. MINNEAPOLIS - May 1, 2013 - Medtronic today announced that 10 students have been selected as 2013 Medtronic Scholars. Each will receive a four-year scholarship totaling $16,000, as well as support services to assist them in their collegiate studies. Students represent nine Twin Cities' north suburban high schools, and one Minneapolis high school. The class of 2013 Medtronic Scholars will be honored at a May 6,... |
| |
| 05/01/13 | Medtronic Partners with National Institute of Hospital Administration in China to Develop Diabetes Care Pathway| MINNEAPOLIS - May 1, 2013 - Medtronic, Inc. (NYSE: MDT) announced today it has entered into an innovative partnership with the National Institute of Hospital Administration, an important think tank under China's National Health and Family Planning Commission, to carry out a series of research projects focusing on building an integrated care pathway for patients with Type 1 diabetes. This effort is an example of a partnership focused on working with an important organization to access data that c... |
| |
| 04/29/13 | Medtronic Introduces New MAST ALIGNED(SM) Procedure for Minimally Invasive Multi-Level Spinal Fusions| MEMPHIS, TENN. - April 29, 2013- Medtronic, Inc. (NYSE: MDT) the world leader in spinal technology announced today the global launch of the MAST ALIGNEDSM procedure. This comprehensive surgical solution includes technologies to access the spine, such as oblique lateral, as well as interbody, navigation, and biologics options. At the core of the MAST ALIGNEDSM procedure is the new CD HORIZON® LONGITUDE® II System, a multi-level percutaneous fixation system designed to provide spinal stabilization... |
| |
| 04/29/13 | Medtronic Reports Initial Implants of Novel Stent Graft for Aortic Aneurysms Involving Branch Vessel| FDA's Early Feasibility Pilot Program for New Medical Devices Encourages Clinical Studies of Innovative Technology to Occur First in U.S. MINNEAPOLIS -- April 29, 2013 -- Vascular specialists at Carolinas HealthCare System in Charlotte, N.C., and the Cleveland Clinic in Ohio recently performed the initial implants of a novel stent graft system from Medtronic, Inc. (NYSE: MDT) as part of a U.S. Food and Drug Administration (FDA) initiative designed to encourage more early-stage clinical research... |
| |
| 04/29/13 | Medtronic Expands Top Cervical-Upper Thoracic System| MEMPHIS, TENN. - April 29, 2013- Medtronic, Inc. (NYSE: MDT) the world leader in spinal technology announced today the U.S. launch of several new product line additions to the VERTEX SELECT® Reconstruction System. The announcement was made at the 81st American Association of Neurological Surgeons (AANS) Annual Scientific Meeting in New Orleans. This compliment to the VERTEX SELECT® Reconstruction System adds an additional selection of various size implants including pre-cut/bent rods, tapered ... |
| |
| 04/24/13 | The New England Journal of Medicine: Medtronic Biventricular Pacing Delivers Better Patient Outcomes for Those with AV Block and Reduced Pumping Function| MINNEAPOLIS - April 24, 2013 - Biventricular (BiV) pacing with Medtronic, Inc. (NYSE: MDT) cardiac resynchronization therapy (CRT) devices may offer a significant clinical advantage and improved patient outcomes over conventional right ventricular (RV) pacing among patients with left ventricular (LV) systolic dysfunction and atrioventricular (AV) block who are indicated for a pacemaker. Results from the Medtronic-sponsored BLOCK HF trial show a 26 percent relative risk reduction in the composite... |
| |
| 04/24/13 | Medtronic Elects Scott C. Donnelly to the Board of Directors| MINNEAPOLIS - April 24, 2013 - Medtronic, Inc. (NYSE: MDT) today announced that its Board of Directors unanimously elected Scott C. Donnelly, chairman and CEO of Textron, Inc., a multi-industry company in the aircraft, defense, automobile, industrial and finance businesses worldwide, to the Board as an independent director, effective July 1, 2013. Mr. Donnelly has been president and CEO of Textron since 2009 and chairman of the Board of Directors since 2010, having previously served there since... |
| |
| 04/15/13 | American College of Cardiology Journal Publishes Outcomes of Diabetes Patients Treated with Medtronic's Resolute Stent| Implanted Medical Device for Coronary Artery Disease Performed As Well In Study Subjects With Diabetes Who Were Not Taking Insulin As In Those Without Diabetes MINNEAPOLIS -- April 15, 2013 -- The current issue of JACC: Cardiovascular Interventions, a peer-reviewed journal published by the American College of Cardiology, includes an article that describes how the Resolute Integrity drug-eluting stent from Medtronic, Inc. (NYSE: MDT) became the first and only device of its kind to be approved by... |
| |
| 04/11/13 | Medtronic Initiates U.S. Trial to Evaluate the Use of Subcutaneous Peripheral Nerve Stimulation for Chronic Back Pain| MINNEAPOLIS - April 11, 2013 - Medtronic, Inc. (NYSE: MDT) today announced the first patient enrollments in the SubQStim II pivotal clinical trial to pursue U.S. Food and Drug Administration (FDA) approval of peripheral nerve stimulation (PNS), also known as subcutaneous nerve stimulation (SQS), for the reduction of chronic, intractable post-surgical back pain. PNS involves an implant of electrical leads just under the skin of the lower back. These leads are connected to a stimulator which d... |
| |
| 04/09/13 | CardioGuide System Enables Real-Time Navigation of Left Ventricular Leads During Medtronic CRT Implants| System Available in U.S. and Canada MINNEAPOLIS - April 9, 2013 - Medtronic, Inc. (NYSE:MDT) today announced market release of the CardioGuide(TM) Implant System, a novel real-time navigation system for cardiac resynchronization therapy pacemakers and defibrillators (CRT-P and CRT-D), in the United States and Canada. The system helps physicians determine the most appropriate location for left-ventricular lead placement by generating 3-D images of the cardiac veins; enhanced software for the sys... |
| |
| 04/09/13 | Medtronic's Endurant 'AAA' Stent Graft Shows Sustained Durability in Complex Patients| Analysis of ENGAGE Registry Found Similarly Strong Outcomes with Device for Endovascular Treatment of Abdominal Aortic Aneurysms in Short and Standard Neck Lengths MINNEAPOLIS -- April 9, 2013 -- Presented to endovascular specialists at the 35th Charing Cross International Symposium in London, a new analysis of clinical data on the Endurant AAA Stent Graft System from Medtronic, Inc. (NYSE: MDT) demonstrates the implanted medical device's consistent and compelling performance in treating abdomi... |
| |
| 04/04/13 | Medtronic Receives 'CE' Mark for Sentrant Introducer Sheath, Complementing Market-Leading Aortic Stent Grafts| Distinguishing Features of New Accessory for Endovascular Interventions Include Optimal Seal for Superior Hemostasis and Reinforced Coil for Proven Kink Resistance MINNEAPOLIS -- April 4, 2013 -- Complementing its market-leading portfolio of stent grafts for the endovascular repair of aortic aneurysms and related conditions, Medtronic, Inc. (NYSE: MDT) announced today that the Sentrant Introducer Sheath has received the CE (Conformité Européenne) mark and will soon be launched internationally. ... |
| |
| 04/02/13 | Medtronic Announces FDA Clearance and First Uses of New Oxygenation System for Adult Cardiac Surgery| New System Designed for Patient Safety, Ease of Use During Open-Heart Procedures MINNEAPOLIS - April 2, 2013 - Medtronic, Inc. (NYSE: MDT) today announced U.S. Food and Drug Administration (FDA) 510(k) clearance and the first U.S. clinical uses of its new Affinity Fusion® oxygenation system. This system, which is designed to serve as a patient's lungs by oxygenating and removing carbon dioxide from blood during various open-heart surgical procedures, incorporates numerous innovations for patien... |
| |
| 03/19/13 | Medtronic Announces Public Offering of Senior Notes| MINNEAPOLIS -- March 19, 2013 -- Medtronic, Inc. (NYSE:MDT) today announced a registered offering of $1.0 billion of its 1.375% Senior Notes due 2018, $1.25 billion of its 2.750% Senior Notes due 2023 and $750 million of its 4.000% Senior Notes due 2043 (collectively, the "Notes"). The closing of the offering is expected to occur on March 26, 2013, subject to satisfaction of customary closing conditions. Medtronic intends to use the net proceeds for working capital and general corp... |
| |
| 03/11/13 | With Medtronic Resolute Stent, Interrupting Dual Antiplatelet Therapy After One Month Showed No Increased Safety Risk in Robust Analysis| ACC.13 Presentation Features Unprecedented Data on Nearly 5,000 Patients, Including "All Comers," from Global RESOLUTE Clinical Program SAN FRANCISCO -- March 11, 2013 -- Cardiologists at ACC.13 learned today that patients with coronary artery disease who received a Resolute drug-eluting stent from Medtronic, Inc. (NYSE: MDT) as participants in one of several clinical studies and interrupted or discontinued their dual antiplatelet therapy after one month of the implant procedure sh... |
| |
| 03/10/13 | New Data Reinforce Significant Blood Pressure Reduction Sustained to Two Years Using the Symplicity(TM) Renal Denervation System| 24-Month Clinical Update from Symplicity HTN-2 Presented Today at the 62nd Annual Scientific Session of the American College of Cardiology MINNEAPOLIS and SAN FRANCISCO - March 10, 2013 - Medtronic, Inc. (NYSE: MDT) today announced 24-month data from Symplicity HTN-2, the first randomized clinical trial investigating renal denervation. Presented for the first time today at the 62nd Annual Scientific Session of the American College of Cardiology, the data show patients treated with the Sympli... |
| |
| 03/08/13 | Medtronic CFO Gary Ellis to Speak at Barclays Global Healthcare Conference| MINNEAPOLIS - Mar 8, 2013 - Medtronic, Inc. (NYSE: MDT), the world's leading medical technology company, today announced it will participate in the Barclays Global Healthcare Conference on Wednesday, March 13, 2013, in Miami. Gary Ellis, senior vice president and chief financial officer of Medtronic, will make a presentation about Medtronic beginning at 3:15 p.m. EDT (2:15 p.m. CDT). A live audio webcast of the presentation will be available on March 13, 2013, by clicking on the Investors l... |
| |
| 03/07/13 | Medtronic Submits IDE to FDA for U.S. Randomized Clinical Trial for Uncontrolled Hypertension Patients with Systolic Blood Pressure Between 140-160 mm Hg| IDE Submission for Symplicity HTN-4 Expands the Indicated Patient Population and Builds upon Medtronic's Rigorous Global Clinical Trial Program for Hypertension Treatment MINNEAPOLIS - March 7, 2013 - Medtronic, Inc. (NYSE: MDT), announced today that the company has submitted an Investigational Device Exemption (IDE) to the U.S. Food and Drug Administration (FDA) to study the Symplicity(TM) renal denervation system for the treatment of uncontrolled hypertension in patients with systolic bloo... |
| |
| 03/06/13 | Symplicity(TM) Renal Denervation System One of First Devices Accepted to Participate in Concurrent Review for Joint FDA Premarket Approval and Medicare National Coverage Determination| FDA-CMS Parallel Review Program Designed to Enable Efficient and Earlier Patient Access to Innovative Medical Advancements MINNEAPOLIS - March 6, 2013 - Medtronic, Inc. (NYSE: MDT) today announced the U.S. Food and Drug Administration (FDA)and the Centers for Medicare & Medicaid Services (CMS) have accepted the inclusion of the Symplicity(TM) renal denervation system for treatment-resistant hypertension in their parallel review program, which will allow CMS to begin consideration for nati... |
| |
| 03/05/13 | Medtronic Announces CE Mark and European Launch of Attain Performa® Portfolio of Quadripolar Leads | New Lead Portfolio Provides Options for Physicians to Deliver CRT Optimally and Efficiently MINNEAPOLIS - March 5, 2013 - Medtronic, Inc. (NYSE: MDT) today announced it has received CE (Conformité Européenne) Mark and will begin the European launch of the Attain Performa® portfolio of quadripolar leads. Paired with Medtronic Viva®/Brava® Quad cardiac resynchronization therapy defibrillators (CRT-D), Attain Performa left-heart leads provide additional options for physicians as they navigate d... |
| |
| 03/04/13 | Medtronic Seeking Long-Distance Runners Who Benefit from Medical Technology| "Global Heroes" Will Receive Entry and Travel to the Medtronic Twin Cities Marathon or Medtronic TC 10 Mile in October MINNEAPOLIS - March 4, 2013 - Medtronic, Inc. (NYSE: MDT) announced today it is recruiting runners from around the world who benefit from medical technology to participate in the eighth annual Medtronic Global Heroes program. Up to 25 runners will be selected to receive a paid entry for themselves and a guest to the Medtronic Twin Cities Marathon or the Medtronic ... |
| |
| 03/04/13 | Medtronic Approved to Update Resolute Integrity Stent's 'CE' Mark Labeling on Dual Antiplatelet Therapy | Interruption or Discontinuation After One Month Following Implant Procedure Posed 'Low and No Increased Risk' of Stent Thrombosis at One Year in Clinical Studies MINNEAPOLIS -- March 4, 2013 -- Of relevance to the clinical practice of interventional cardiology, Medtronic, Inc. (NYSE: MDT) announced today that it has received regulatory approval to update the CE (Conformité Européenne) mark labeling for the Resolute Integrity drug-eluting stent with new information on one month of dual antipla... |
| |
| 02/28/13 | Medtronic EVP & President Chris O'Connell to Speak at Cowen Healthcare Conference| MINNEAPOLIS - Feb. 28, 2013 - Medtronic, Inc. (NYSE: MDT), the world's leading medical technology company, today announced it will participate in the Cowen and Company 33rd Annual Healthcare Conference on Wednesday, March 6, 2013, in Boston. Chris O'Connell, executive vice president and president of Medtronic's Restorative Therapy Group, will make a presentation about Medtronic beginning at 10:00 a.m. EST (9:00 a.m. CST). A live audio webcast of the presentation will be available on March 6... |
| |
| 02/28/13 | Medtronic Announces CE Mark for Engager(TM) Transcatheter Valve| New Valve Provides Transapical Option for Physicians Treating Patients with Aortic Stenosis MINNEAPOLIS - February 28, 2013 - Medtronic, Inc. (NYSE: MDT) today announced CE (Conformité Européenne) Mark of the Engager Transcatheter Aortic Valve Implantation (TAVI) System with transapical delivery catheter to treat patients with severe aortic stenosis who are at high or extreme risk for surgical aortic valve replacement (SAVR). The new valve demonstrated positive clinical outcomes in its Europ... |
| |
| 02/27/13 | Meta-Analysis Demonstrates Efficacy of Pillar Procedure for the Treatment of Snoring and Mild to Moderate Obstructive Sleep Apnea| Authors Reach Conclusions After a Meta-Analysis of 7 Clinical Studies for Snoring, and 7 Studies for OSA MINNEAPOLIS - Feb. 27, 2013 - In a meta-analysis of seven studies published in the January issue of Laryngoscope, Ji Ho Choi, M.D., Ph. D., and coauthors conclude that the Medtronic Pillar Procedure significantly reduced snoring loudness and mild-to-moderate obstructive sleep apnea (OSA). The Medtronic Pillar Procedure was cleared by the Food and Drug Administration (FDA) as a treatment... |
| |
| 02/26/13 | Medtronic Gains First FDA Approval to Conduct Early Feasibility Medical Device Study| Shared Commitment to Innovation Enables Early Study of Novel Native Outflow Tract Transcatheter Pulmonary Valve in Patients with Pulmonary Valve Failure MINNEAPOLIS - February 26, 2013 - Medtronic, Inc. (NYSE: MDT) today announced that it has received U.S. Food and Drug Administration (FDA) approval to conduct an early feasibility study using the Medtronic Native Outflow Tract Transcatheter Pulmonary Valve (TPV). This approval represents the first-ever FDA approval of an investigational devi... |
| |
| 02/25/13 | Medtronic CFO Gary Ellis to Speak at Citi Global Healthcare Conference| MINNEAPOLIS - Feb. 25, 2013 - Medtronic, Inc. (NYSE: MDT), the world's leading medical technology company, today announced it will participate in the Citi Global Healthcare Conference on Wednesday, February 27, 2013, in New York City. Gary Ellis, senior vice president and chief financial officer of Medtronic, will make a presentation about Medtronic beginning at 9:35a.m. EST (8:35a.m. CST). A live audio webcast of the presentation will be available on February 27, 2013, by clicking on the I... |
| |
| 02/25/13 | FDA Approves Longer Lengths of Medtronic's Resolute Integrity Stent| New Sizes of Implantable Medical Device Target Long Coronary Lesions Common Among Diabetes Patients MINNEAPOLIS -- Feb. 25, 2013 -- Expanding the applicability of its marquee product for the interventional treatment of coronary artery disease in the United States, Medtronic, Inc. (NYSE: MDT) announced today that the U.S. Food and Drug Administration (FDA) has approved the 34mm and 38mm lengths of the Resolute Integrity drug-eluting stent in diameters of 3.0mm, 3.5mm and 4.0mm with an indicat... |
| |
| 02/19/13 | Medtronic Reports Third Quarter Earnings| Revenue of $4.0 Billion Grew 4% on a Constant Currency Basis; 3% as Reported International Revenue Grew 7% on a Constant Currency Basis; 5% as Reported Emerging Market Revenue Grew 21% on a Constant Currency Basis; 20% as Reported Non-GAAP Diluted EPS Growth of 11%; GAAP Diluted EPS Growth of 10% Free Cash Flow of $1.4 Billion; GAAP Cash Flow from Operations of $1.5 Billion MINNEAPOLIS - February 19, 2013 - Medtronic, Inc. (NYSE: MDT) today announced financial results for its thir... |
| |
| 02/14/13 | Medtronic Announces Cash Dividend for Fourth Quarter of Fiscal Year 2013| MINNEAPOLIS - February 14, 2013 - The board of directors of Medtronic, Inc. (NYSE:MDT) today approved a cash dividend of $0.26 per share of the Company's common stock. The dividend is payable on April 26, 2013, to shareholders of record at the close of business on April 5, 2013. About MedtronicMedtronic, Inc. (www.medtronic.com), headquartered in Minneapolis, is the global leader in medical technology - alleviating pain, restoring health, and extending life for millions of people around the ... |
| |
| 02/13/13 | AIRvance(TM) Bone Screw System Gains Additional FDA Clearance | The AIRvance(TM) Bone Screw System Is Now Suitable for the Performance of a Hyoid Suspension Procedure, Which Can Be Used in Combination with Other Procedures for the Treatment of Obstructive Sleep Apnea MINNEAPOLIS - Feb. 13, 2013 - Medtronic announced today that it has received Food and Drug Administration (FDA) clearance for its AIRvance(TM) Bone Screw System that allows surgeons to perform a hyoid suspension procedure independently or in combination with other procedures for the treatmen... |
| |
| 02/13/13 | Medtronic Announces FDA Approval and Launch of Its Advisa MRI Pacemaker System| Second-generation MR-Conditional Pacemaker Combines Advanced Pacing Technology with MRI Access MINNEAPOLIS - February 13, 2013 - Showcasing its leadership position in pacing technologies, Medtronic, Inc. (NYSE: MDT), today announced the U.S. Food and Drug Administration (FDA) approval and U.S. launch of its Advisa DR MRI(TM) SureScan® pacing system. The Advisa MRI system is Medtronic's second-generation MR-Conditional pacemaker and is the first system to combine the most advanced pacing tech... |
| |
| 02/11/13 | Medtronic to Announce Financial Results for Its Third Quarter of Fiscal Year 2013| MINNEAPOLIS - Feb. 11, 2013 - Medtronic, Inc. (NYSE: MDT) announced today it will report financial results for the third quarter of its fiscal year 2013 on Tuesday, February 19, 2013. A news release will be issued at approximately 6:15 a.m. Central Time and will be available at www.medtronic.com/newsroom. The earnings news release will include summary financial information for Medtronic's third quarter, which ended January 25, 2013. Medtronic will host a webcast at 7 a.m. Central Time to disc... |
| |
| 02/05/13 | Minnesota Timberwolves Star Ricky Rubio Teams Up with Medtronic Foundation to Save Young Lives from Sudden Cardiac Arrest| Rubio Helps Web Visitors Save a "Virtual" Life at HeartRescueNow.com MINNEAPOLIS, February 5, 2013 -Minnesota Timberwolves basketball star Ricky Rubio joins the Medtronic Foundation this February in saving young lives worldwide from sudden cardiac arrest (SCA). Through the Foundation's HeartRescue Project, Rubio will lend a "virtual" hand in teaching the public how to respond quickly to an SCA emergency. Sudden Cardiac Arrest is the leading cause of death in young athl... |
| |
| 02/04/13 | Medtronic Announces CE Mark of Evera® Portfolio of Implantable Cardioverter-Defibrillators| Next-Generation ICDs Offer Patients Proven Treatment Performance, Increased Longevity, Improved Comfort MINNEAPOLIS - February 4, 2013 - Medtronic today announced CE (Conformité Européenne) Mark of the Evera® portfolio of implantable cardioverter-defibrillators (ICD). With increased longevity and the most advanced shock reduction technology available, the new family of ICDs is the first to feature the PhysioCurve® design, a contoured shape with thin, smooth edges that better fits inside ... |
| |
| 01/30/13 | Medtronic Completes Strategic Investment in LifeTech Scientific Corporation| Strategic Alliance to Leverage Best of Both Companies to ReachCardiovascular Patients in China and Other Emerging Markets MINNEAPOLIS and Shenzhen - January 30, 2013 - Medtronic, Inc. (NYSE:MDT) and LifeTech Scientific Corporation (8122:HK) today announced the closing of a transaction creating a strategic alliance thatbrings together the resources and technologies of the world's largest medical device company with the local market expertise, brand recognition and growth potential of a recogn... |
| |
| 01/30/13 | Medtronic Introduces the First and Only Neurostimulation Systems with CE Mark Approval for Full-Body MRI Scans| TOLOCHENAZ AND MINNEAPOLIS - January 30, 2013 - Medtronic, Inc. (NYSE: MDT) today introduced in Europe the first and only implantable neurostimulation systems indicated for use in the treatment of chronic back and/or leg pain that are designed for full-body Magnetic Resonance Imaging (MRI) scans under specific conditions. The first new system implants have been performed by Dr. JP Van Buyten and Dr. Iris Smet in Belgium; Dr. Rasche and Professor Tronnier in Germany; Dr. J. De Andres in Spain;... |
| |
| 01/28/13 | Medtronic Initiates Landmark Study of Neurostimulation Therapy for Failed Back Surgery Syndrome| First Patients Treated in Global Clinical Trial Evaluating Impact of Therapy on Predominant Low Back Pain MINNEAPOLIS - January 28, 2013 - Medtronic, Inc. (NYSE: MDT) today announced the start of PROMISE, a Prospective, Randomized Study of Multicolumn Implantable Lead Stimulation for Predominant Low Back Pain. This is the first-ever, large-scale study comparing the effectiveness of Medtronic neurostimulation therapy with Specify® 5-6-5 multicolumn surgical leads plus optimal medical managemen... |
| |
| 01/24/13 | Medtronic Launches Lower-Extremity Indication for Complete 'SE' Vascular Stent Internationally| Self-Expanding Peripheral Device Gets CE Mark for Superficial Femoral and Proximal Popliteal Arteries MINNEAPOLIS -- Jan. 24, 2013 -- Expanding its role in the treatment of peripheral artery disease, Medtronic, Inc. (NYSE: MDT) today announced the CE (Conformité Européene) mark and international launch of its Complete SE (self-expanding) vascular stent for use in the lower extremities -- specifically, the superficial femoral arteries (SFA) and proximal popliteal arteries (PPA), which supply b... |
| |
| 01/23/13 | Medtronic Drug-Eluting Balloon Study Completes Enrollment| Milestone in IN.PACT SFA II Brings FDA Submission for Promising Interventional Treatment of Peripheral Artery Disease One Step Closer in U.S. MINNEAPOLIS -- Jan. 23, 2013 -- Medtronic, Inc. (NYSE: MDT), today announced completion of enrollment in IN.PACT SFA II, the U.S. arm of its clinical study for the IN.PACT Admiral drug-eluting balloon as a treatment for peripheral artery disease in the superficial femoral and proximal popliteal arteries (SFA and PPA). IN.PACT SFA II is a prospective... |
| |
| 01/16/13 | New Clinical Trial Will Use Continuous Cardiac Monitoring to Evaluate Atrial Fibrillation in High-Risk Patients| Medtronic Announces First Patient Implant in REVEAL AF Clinical Trial MINNEAPOLIS - January 16, 2013 - Medtronic, Inc. (NYSE: MDT) today announced the first patient implant for the REVEAL AF (Incidence of AF in High Risk Patients) Clinical Trial, which through continuous cardiac monitoring will evaluate the incidence of atrial fibrillation among patients suspected to be at a high-risk for the disease, and will identify key patient predictors for detection of AF. Using the Reveal® Insertable ... |
| |
| 01/15/13 | Medtronic Announces Launch of FlexCath Advance(TM) Steerable Sheath, Enhancing the Arctic Front Advance(TM) Cryoballoon System| Second-Generation Sheath May Facilitate Easier Access to the Inferior Veins When Treating Paroxysmal Atrial Fibrillation MINNEAPOLIS - Jan. 15, 2013 - Medtronic, Inc. (NYSE: MDT) today announced Food and Drug Administration (FDA) clearance and U.S. launch of the FlexCath Advance(TM) Steerable Sheath, a new enhancement to the Arctic Front Advance(TM) Cryoballoon System. This second-generation sheath has an increased degree of deflection and response, providing greater ease compared to the prev... |
| |
| 01/10/13 | New Clinical Trial First To Evaluate Effectiveness of CRT-P in Symptomatic Heart Failure Patients with Mild-to-Moderate Structural Heart Disease| Medtronic-Sponsored Study Aims to Support Worldwide Indication Expansion for CRT-P in a Significantly Underserved Heart Failure Patient Population MINNEAPOLIS - Jan. 10, 2013 - Medtronic, Inc. (NYSE: MDT) today announced the first patient enrollment in MIRACLE EF, a global clinical trial that will evaluate the effectiveness of cardiac resynchronization therapy-pacemakers (CRT-Ps) in delaying the progression of heart failure in symptomatic patients with mildly reduced heart pumping function. T... |
| |
| 01/07/13 | Medtronic Updates Fiscal 2013 EPS Guidance| MINNEAPOLIS - January 7, 2013 - In a presentation to investors, Medtronic, Inc. (NYSE:MDT) today updated diluted earnings per share (EPS) guidance for fiscal year 2013. The Company tightened its fiscal 2013 diluted EPS guidance range to $3.66 to $3.70 from the previously stated range of $3.62 to $3.70. The new range implies annual EPS growth of 6 to 7%. Management indicated that the Company's updated fiscal 2013 EPS guidance is based on the positive financial impact from the recent renewal ... |
| |
